摘要
目的:研究培美曲塞加顺铂术前新辅助化疗对肺腺癌患者近期疗效及癌胚抗原(CEA)水平的影响。方法:选择2018年1月-2020年1月本院收治的80例肺腺癌患者纳入研究。依据随机数字表法将患者分为研究组和对照组,每组40例。对照组实施紫杉醇加顺铂新辅助化疗,研究组实施培美曲塞加顺铂术前新辅助化疗。比较两组近期疗效,治疗前后血清CEA水平,毒副反应发生情况,治疗前后血清细胞角蛋白-19片段抗原(CYFRA21-1)、糖类抗原199(CA199)水平。结果:研究组近期总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清CEA水平均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05)。研究组白细胞减少、中性粒细胞减少、血小板减少、脱发、皮疹以及便秘发生率均低于对照组,差异均有统计学意义(P<0.05)。治疗后,研究组血清CYFRA21-1和CA199水平均低于对照组,差异均有统计学意义(P<0.05)。结论:培美曲塞加顺铂术前新辅助化疗可有效提高肺腺癌患者近期疗效,同时有利于下调CEA以及CYFRA21-1、CA199水平,降低毒副反应发生率。
Objective:To study the effect of Pemetrexed plus Cisplatin preoperative neoadjuvant chemotherapy on short-term efficacy and carcinoembryonic antigen(CEA)level in patients with lung adenocarcinoma.Method:A total of 80 patients with lung adenocarcinoma admitted to our hospital from January 2018 to January 2020 were included in the study.Patients were divided into study group and control group according to random number table method,with 40 cases in each group.The control group received paclitaxel plus Cisplatin neoadjuvant chemotherapy,and the study group received Pemetrexed plus Cisplatin preoperative neoadjuvant chemotherapy.The short-term efficacy,serum CEA level before and after treatment,the occurrence of toxic and side reactions,and the levels of CYFRA21-1 and CA199 in serum before and after treatment were compared between the two groups.Result:The short-term total effective rate of the study group was higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,serum CEA levels in both groups were lower than before treatment,and the study group was lower than the control group,the differences were statistically significant(P<0.05).The incidence of leukopenia,neutropenia,thrombocytopenia,alopecia,rash and constipation in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CYFRA21-1 and CA199 in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Pemetrexed plus Cisplatin preoperative neoadjuvant chemotherapy can effectively improve the short-term efficacy of patients with lung adenocarcinoma,reduce the levels of CEA,CYFRA21-1 and CA199,and reduce the incidence of toxic and side effects.
作者
张大勇
ZHANG Dayong(The Second Hospital of Chaoyang City,Chaoyang 122000,China)
出处
《中国医学创新》
CAS
2021年第27期9-13,共5页
Medical Innovation of China
关键词
肺腺癌
培美曲塞
顺铂
新辅助化疗
癌胚抗原
Lung adenocarcinoma
Pemetrexed
Cisplatin
Neoadjuvant chemotherapy
Carcinoembryonic antigen
作者简介
通信作者:张大勇。
